ARTICLE | Distillery Therapeutics
Neurology
January 9, 2018 10:06 PM UTC
Patient sample and cell culture studies suggest a synthetic transcription elongation factor that induces FXN expression could help treat Friedreich’s ataxia. The synthetic molecule consists of a small...